EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
EXOZYMES INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.00−0.09 (-2.20%)
Close on Oct 19, 2026
- Market cap
- $34.64M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1.3%
0M of 9M shares
Institutional holders
9
2 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 2 sales
Net sold $9.02K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tyler Korman | 832,569 | 8.74% | 13D (active) | Nov 14, 2024 |
| Paul Opgenorth | 744,333 | 7.81% | 13D (active) | Nov 14, 2024 |
| James U Bowie | 597,388 | 6.27% | 13D (active) | Nov 14, 2024 |
| Christopher A. Marlett | 4,155,904 | 43.61% | 13D (active) | Nov 14, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EXOZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 54,985 | 0.59% | $463.52K | +32,795 | 0.00% |
| Davidson Kahn Capital Management, LLC | 25,000 | 0.27% | $210.75K | New | 0.09% |
| Geode Capital Management, LLC | 23,406 | 0.25% | $197.31K | +1,515 | 0.00% |
| BlackRock, Inc. | 9,610 | 0.10% | $81.01K | +2,813 | 0.00% |
| Vanguard Fiduciary Trust Co | 9,426 | 0.10% | $79.46K | – | 0.00% |
| Morgan Stanley | 1,250 | 0.01% | $10.54K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 349 | 0.00% | $2.94K | −968 | 0.00% |
| UBS Group AG | 203 | 0.00% | $1.71K | +179 | 0.00% |
| Barclays PLC | 75 | 0.00% | $632 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 1.3% | 2 / 4 | 1 / 0 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.7% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q4 2025 | 7 | 0M | 0.7% | 1 / 3 | 2 / 0 | 0M | 0M |
| Q3 2025 | 6 | 0M | 0.6% | 0 / 3 | 2 / 3 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.8% | 3 / 4 | 2 / 0 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.8% | 1 / 3 | 2 / 2 | 0M | 0M |
| Q4 2024 | 7 | 0M | 1.1% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EXOZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 25,879 | 0.28% | $218.16K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 22,342 | 0.24% | $188.34K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 10,311 | 0.11% | $100.53K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 9,167 | 0.10% | $77.28K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 2,944 | 0.03% | $28.70K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,018 | 0.02% | $19.68K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,997 | 0.02% | $19.47K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 443 | 0.00% | $3.73K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mohammad Hayat | President & Chairman of Board, Director | 155,818 | 1.68% | Nov 18, 2024 |
| Fouad Nawaz | Vice President- Finance | 9,488 | 0.10% | Sep 17, 2026 |
| Michael Heltzen | Chief Executive Officer | 14,708 | 0.16% | Sep 2, 2026 |
| Tyler Paz Korman | Chief Scientific Officer | 762,837 | 8.22% | Aug 25, 2026 |
| Damien Alan Perriman | Chief Commercial Officer | 28,499 | 0.31% | Aug 25, 2026 |
| Paul Hideo Opgenorth | Vice President, Development | 645,149 | 6.95% | Apr 8, 2026 |
| Edgardo Javier Rayo | Director | 77,909 | 0.84% | Mar 25, 2025 |
| Lon E. Bell | Director | – | – | Nov 19, 2024 |
| Christopher A. Marlett | Director, 10% owner | 3,808,476 | 41.03% | Nov 18, 2024 |
| James Joseph Lalonde | Director | – | – | Nov 18, 2024 |
| James Ulrich Bowie | Director | 577,910 | 6.23% | Nov 18, 2024 |
| Anthony Digiandomenico | Director, 10% owner | 3,808,476 | 41.03% | Nov 18, 2024 |
| MDB Capital Holdings, LLC | 10% owner | 3,931,133 | 42.36% | Nov 18, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +4 | $7.58 | $30 | 14,708 |
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +250 | $7.60 | $1.90K | 14,453 |
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +251 | $7.35 | $1.84K | 14,704 |
| Michael Heltzen Chief Executive Officer | Aug 25, 2026 | Buy | +250 | $7.52 | $1.88K | 14,203 |
| Michael Heltzen Chief Executive Officer | Aug 25, 2026 | Buy | +100 | $7.50 | $750 | 13,953 |
| Michael Heltzen Chief Executive Officer | Aug 19, 2026 | Award | +8,841 | $6.40 | $56.58K | 13,853 |
| Tyler Paz Korman Chief Scientific Officer | Aug 19, 2026 | Option exercise | +32,964 | – | – | 762,837 |
| Damien Alan Perriman Chief Commercial Officer | Aug 19, 2026 | Option exercise | +19,612 | – | – | 28,499 |
| Tyler Paz Korman Chief Scientific Officer | Apr 9, 2026 | Sale | −750 | $10.53 | $7.90K | 729,123 |
| Tyler Paz Korman Chief Scientific Officer | Apr 8, 2026 | Sale | −750 | $10.04 | $7.53K | 729,873 |
| Damien Alan Perriman Chief Commercial Officer | Apr 1, 2026 | Award | +62,759 | – | – | 62,759 |
| Tyler Paz Korman Chief Scientific Officer | Apr 1, 2026 | Award | +5,332 | $8.44 | $45.00K | 730,623 |
| Paul Hideo Opgenorth Vice President, Development | Apr 1, 2026 | Award | +3,999 | $8.44 | $33.75K | 645,149 |
| Damien Alan Perriman Chief Commercial Officer | Apr 1, 2026 | Award | +8,887 | $8.44 | $75.01K | 0 |
| Fouad Nawaz Vice President- Finance | Apr 1, 2026 | Award | +5,999 | $8.44 | $50.63K | 9,488 |
| Michael Heltzen Chief Executive Officer | Jul 2, 2025 | Buy | +1,040 | $10.22 | $10.63K | 10,629 |
| Tyler Paz Korman Vice President, Research | Jun 16, 2025 | Award | +2,990 | $12.54 | $37.49K | 725,291 |
| Paul Hideo Opgenorth Vice President, Development | Jun 13, 2025 | Award | +2,990 | $12.54 | $37.49K | 641,150 |
| Fouad Nawaz Vice President, Finance | Jun 13, 2025 | Award | +3,489 | $12.54 | $43.75K | 3,489 |
| Michael Heltzen Chief Executive Officer | Jan 17, 2025 | Buy | +1,767 | $10.78 | $19.05K | 3,872 |
| Michael Heltzen Chief Executive Officer | Jan 16, 2025 | Buy | +121 | $10.72 | $1.30K | 2,105 |
| Michael Heltzen Chief Executive Officer | Nov 15, 2024 | Buy | +1,984 | $11.10 | $22.02K | 1,984 |
| MDB Capital Holdings, LLC 10% owner | Nov 8, 2024 | Conversion | +122,657 | $6.40 | $785.00K | 3,931,133 |
| Paul Hideo Opgenorth Vice President, Development | Nov 8, 2024 | Conversion | +2,344 | $6.40 | $15.00K | 640,504 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.